Curr Infect Dis Rep (2012) 14:275–283 65. Kohno S, Kida H, Mizuguchi M, et al. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 2010;54:4568– 74. 66. Watanabe A, Chang SC, Kim MJ, et al. Long-acting neuramini- dase inhibitor laninamivir octanoate versus oseltamivir for treat- ment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis. 2010;51:1167–75. 67. Kandun IN, Tresnaningsih E, Purba WH, et al. Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series. Lancet. 2008;372:744–9. 68. Liem NT, Tung CV, Hien ND, et al. Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006. Clin Infect Dis. 2009;48:1639–46. 69. WHO. Clinical management of human infection with avian influenza A (H5N1) virus (15 August 2007). Available at http://www.who.int/influ enza/resources/documents/clinical_management_h5n1_15_08_2007/en/ index.html. Accessed: November 2011. 70. Centers for Disease Control and Prevention. 2011-2012 influenza antiviral medications: summary for clinicians. Available at http:// www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm. Accessed November 2011. CDC guidelines for the use of antiviral medications for the treatment and prevention of influenza. 283 71. Hurt AC, Lee RT, Leang SK, et al.: Increased detection in Aus- tralia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill 2011, 16. 72. Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats. J Infect Dis. 2011;203:6–10. 73. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guide- lines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27–72. 74. Kumar A, Zarychanski R, Pinto R, et al.: Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009, 302:1872-1879. Canadian prospective study which showed that, during the H1N1 influenza A pandemic, lower respiratory tract compromise was rapidly progressive, oftenly leading to respiratory failure and requiring salvage therapies. 75. Noah MA, Peek GJ, Finney SJ, et al. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). JAMA. 2011;306:1659–68. 76. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Cam- paign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36:296–327.